Drugs / VSV-hIFNbeta-NIS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03120624 | Sep 2017 → Aug 2023 overdue | carcinosarcoma of the corpus uteri, endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, endometrial mixed adenocarcinoma +2 | Mayo Clinic | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VSV-hIFNbeta-NIS | “The study virus, VSV-hIFNbeta-NIS, has been changed so that it has restricted ability to spread to tumor cells and not to healthy cells.” NCT03120624 ↗ |
| Route | Intravenous | “Patients receive VSV-hIFNbeta-NIS IV over 60-90 minutes on day 1.” NCT03120624 ↗ |